New Research on Anxiety Disorders in the Elderly and an Update on Evidence-Based Treatments

Current Psychiatry Reports

Volumn 17, Issue 7, 2015, Pages

  Andreescu, Carmen ^a   Varon, Daniel ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Anxiety disorders; Elderly; Evidence based treatment; Neurobiological research

Indexed keywords

ANXIOLYTIC AGENT; BENZODIAZEPINE; BUSPIRONE; DULOXETINE; ESCITALOPRAM; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; PLACEBO; PREGABALIN; QUETIAPINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

AGED; AGORAPHOBIA; ANXIETY DISORDER; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL RESEARCH; COGNITIVE DEFECT; DELIRIUM; DISABILITY; DISTRESS SYNDROME; DIZZINESS; DRUG TOLERABILITY; DRUG WITHDRAWAL; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENERALIZED ANXIETY DISORDER; HEADACHE; HUMAN; MENTAL DEFICIENCY; MONOTHERAPY; MORTALITY; NAUSEA; NEUROENDOCRINOLOGY; NEUROIMAGING; NEUROPATHOLOGY; NEUROPSYCHOLOGICAL TEST; NEUROPSYCHOLOGY; ORTHOSTATIC HYPOTENSION; PREVALENCE; PSYCHOTHERAPY; REVIEW; RISK FACTOR; SEDATION; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; URINE RETENTION; XEROSTOMIA; ACCEPTANCE AND COMMITMENT THERAPY; ANXIETY; ANXIETY DISORDERS; BRAIN; CARDIOVASCULAR DISEASES; COGNITION DISORDERS; COGNITIVE THERAPY; COMPLICATION; DIFFERENTIAL DIAGNOSIS; EVIDENCE BASED MEDICINE; MENTAL STRESS; MINDFULNESS; NERVE CELL NETWORK; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOCIAL ISOLATION; TREATMENT OUTCOME;

ACCEPTANCE AND COMMITMENT THERAPY; AGED; ANTI-ANXIETY AGENTS; ANXIETY; ANXIETY DISORDERS; BRAIN; CARDIOVASCULAR DISEASES; COGNITION DISORDERS; COGNITIVE THERAPY; DIAGNOSIS, DIFFERENTIAL; EVIDENCE-BASED MEDICINE; HUMANS; MINDFULNESS; NERVE NET; NEUROIMAGING; PREVALENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; SOCIAL ISOLATION; STRESS, PSYCHOLOGICAL; TREATMENT OUTCOME;

EID: 84929415569     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-015-0595-8     Document Type: Review

References (92)

1. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51(1):8–19.
2. Flint AJ. Epidemiology and comorbidity of anxiety disorders in later life: implications for treatment. Clin Neurosci. 1997;4(1):31–6.
3. Le Roux H, Gatz M, Wetherell JL. Age at onset of generalized anxiety disorder in older adults. Am J Geriatr Psychiatry. 2005;13(1):23–30.
4. Wittchen HU, Hoyer J. Generalized anxiety disorder: nature and course. J Clin Psychiatry. 2001;62 Suppl 11:15–9. discussion 20–11.
5. Beekman AT, Bremmer MA, Deeg DJ, et al. Anxiety disorders in later life: a report from the Longitudinal Aging Study Amsterdam. Int J Geriatr Psychiatry. 1998;13(10):717–26.
6. Schuurmans J, Comijs HC, Beekman AT, et al. The outcome of anxiety disorders in older people at 6-year follow-up: results from the Longitudinal Aging Study Amsterdam. Acta Psychiatr Scand. 2005;111(6):420–8.
7. Regier DA, Boyd JH, Burke Jr JD, et al. One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites. Arch Gen Psychiatry. 1988;45(11):977–86.
8. Hunt C, Issakidis C, Andrews G. DSM-IV generalized anxiety disorder in the Australian National Survey of Mental Health and Well-Being. Psychol Med. 2002;32(4):649–59.
9. Zhang X, Norton J, Carriere I, Ritchie K, Chaudieu I, Ancelin ML. Generalized anxiety in community-dwelling elderly: prevalence and clinical characteristics. J Affect Disord. 2014;172C:24–9. Recent epidemiologic study on a large sample, showing a high prevalence of late-life GAD.
10. Bryant C, Jackson H, Ames D. The prevalence of anxiety in older adults: methodological issues and a review of the literature. J Affect Disord. 2008;109(3):233–50.
11. Lambiase MJ, Kubzansky LD, Thurston RC. Prospective study of anxiety and incident stroke. Stroke. 2014;45:438–43. Methodologically sound prospective study showing that higher anxiety symptom levels were associated with increased risk of incident stroke independent of other risk factors, including depression.
12. Tully PJ, Cosh SM, Baune BT. A review of the affects of worry and generalized anxiety disorder upon cardiovascular health and coronary heart disease. Psychol Health Med. 2013;18(6):627–44.
13. Rosenberg PB, Mielke MM, Appleby BS, Oh ES, Geda YE, Lyketsos CG. The association of neuropsychiatric symptoms in MCI with incident dementia and Alzheimer disease. Am J Geriatr Psychiatry. 2013;21(7):685–95. Recent study on a large sample (1,821 participants with MCI) showing that anxiety symptoms were associated with increased risk of incident dementia.
14. Zhang X, Norton J, Carriere I, Ritchie K, Chaudieu I, Ancelin ML. Risk factors for late-onset generalized anxiety disorder: results from a 12-year prospective cohort (The ESPRIT study). Translat Psychiatry. 2015;5. e536.
15. Price RB, Eldreth DA, Mohlman J. Deficient prefrontal attentional control in late-life generalized anxiety disorder: an fMRI investigation. Translat Psychiatry. 2011;1. e46.
16. Mohlman J, Price RB, Eldreth DA, Chazin D, Glover DM, Kates WR. The relation of worry to prefrontal cortex volume in older adults with and without generalized anxiety disorder. Psychiatry Res. 2009;173(2):121–7.
17. Andreescu C, Gross JJ, Lenze E, et al. Altered cerebral blood flow patterns associated with pathologic worry in the elderly. Depress Anxiety. 2011;28(3):202–9.
18. Andreescu C, Sheu LK, Tudorascu D, et al. Emotion reactivity and regulation in late-life generalized anxiety disorder: functional connectivity at baseline and post-treatment. Am J Geriatr Psychiatry. 2015;23(2):200–14.
19. Etkin A, Wager TD. Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am J Psychiatry. 2007;164(10):1476–88.
20. Nitschke JB, Sarinopoulos I, Oathes DJ, et al. Anticipatory activation in the amygdala and anterior cingulate in generalized anxiety disorder and prediction of treatment response. Am J Psychiatry. 2009;166(3):302–10.
21. Etkin A, Prater KE, Schatzberg AF, Menon V, Greicius MD. Disrupted amygdalar subregion functional connectivity and evidence of a compensatory network in generalized anxiety disorder. Arch Gen Psychiatry. 2009;66(12):1361–72.
22. Andreescu C, Sheu LK, Tudorascu D, Gross JJ, Walker S, Banihashemi L, et al. Emotion reactivity and regulation in late-life generalized anxiety disorder: functional connectivity at baseline and post-treatment. Am J Geriatr Psychiatry. 2014.
23. Smith GS, Gunning-Dixon FM, Lotrich FE, Taylor WD, Evans JD. Translational research in late-life mood disorders: implications for future intervention and prevention research. Neuropsychopharmacology. 2007;32(9):1857–75.
24. Andreescu C, Sheu LK, Tudorascu D, Walker S, Aizenstein H. The ages of anxiety—differences across the lifespan in the default mode network functional connectivity in generalized anxiety disorder. Int J Geriatr Psychiatry. 2014;29(7):704–12.
25. Price RB, Mohlman J. Inhibitory control and symptom severity in late life generalized anxiety disorder. Behav Res Ther. 2007;45(11):2628–39.
26. Mohlman J, Price RB, Vietri J. Attentional bias in older adults: effects of generalized anxiety disorder and cognitive behavior therapy. J Anxiety Disord. 2013;27(6):585–91.
27. Lenze EJ, Wetherell JL, Andreescu C. Anxiety disorders. In: Coffey CE, Cummings JL, editors. Textbook of geriatric neuropsychiatry. 3rd ed. Washington DC: American Psychiatric Publishing, Inc; 2011.
28. Cohen D, Eisdorfer C, Vitaliano PP, Bloom V. The relationship of age, anxiety, and serum immunoglobulins with crystallized and fluid intelligence. Biol Psychiatry. 1980;15(5):699–709.
29. Deptula D, Singh R, Pomara N. Aging, emotional states, and memory. Am J Psychiatry. 1993;150(3):429–34.
30. Hogan MJ. Divided attention in older but not younger adults is impaired by anxiety. Exp Aging Res. 2003;29(2):111–36.
31. Mantella RC, Butters MA, Dew MA, et al. Cognitive impairment in late-life generalized anxiety disorder. Am J Geriatr Psychiatry. 2007;15(8):673–9.
32. Caudle DD, Senior AC, Wetherell JL, et al. Cognitive errors, symptom severity, and response to cognitive behavior therapy in older adults with generalized anxiety disorder. Am J Geriatr Psychiatry. 2007;15(8):680–9.
33. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002;288(12):1475–83.
34. Geda YE, Roberts RO, Knopman DS, et al. Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging: population-based study. Arch Gen Psychiatry. 2008;65(10):1193–8.
35. Andreescu C, Teverovsky E, Fu B, Hughes TF, Chang CC, Ganguli M. Old worries and new anxieties: behavioral symptoms and mild cognitive impairment in a population study. Am J Geriatr Psychiatry. 2014;22(3):274–84.
36. Palmer K, Berger AK, Monastero R, Winblad B, Backman L, Fratiglioni L. Predictors of progression from mild cognitive impairment to Alzheimer disease. Neurology. 2007;68(19):1596–602.
37. Palmer K, Di Iulio F, Varsi AE, et al. Neuropsychiatric predictors of progression from amnestic-mild cognitive impairment to Alzheimer’s disease: the role of depression and apathy. J Alzheimers Dis. 2010;20(1):175–83.
38. Pietrzak RH, Lim YY, Neumeister A, Ames D, Ellis KA, Harrington K, et al. Amyloid-beta, anxiety, and cognitive decline in preclinical Alzheimer disease: a multicenter, prospective cohort study. JAMA Psychiatry. 2015;72:284–291. Very recent study showing that elevated anxiety symptoms moderate the effect of beta-amyloid on cognitive decline in preclinical AD, resulting in more rapid decline in several cognitive domains.
39. Wands K, Merskey H, Hachinski VC, Fisman M, Fox H, Boniferro M. A questionnaire investigation of anxiety and depression in early dementia. J Am Geriatr Soc. 1990;38(5):535–8.
40. Hilbert K, Lueken U, Beesdo-Baum K. Neural structures, functioning and connectivity in generalized anxiety disorder and interaction with neuroendocrine systems: a systematic review. J Affect Disord. 2014;158C:114–26.
41. Tafet GE, Idoyaga-Vargas VP, Abulafia DP, et al. Correlation between cortisol level and serotonin uptake in patients with chronic stress and depression. Cogn Affect Behav Neurosci. 2001;1(4):388–93.
42. Terlevic R, Isola M, Ragogna M, et al. Decreased hypothalamus volumes in generalized anxiety disorder but not in panic disorder. J Affect Disord. 2013;146(3):390–4.
43. Knoops AJ, Gerritsen L, van der Graaf Y, Mali WP, Geerlings MI. Basal hypothalamic pituitary adrenal axis activity and hippocampal volumes: the SMART-Medea study. Biol Psychiatry. 2010;67(12):1191–8.
44. Dedovic K, Duchesne A, Andrews J, Engert V, Pruessner JC. The brain and the stress axis: the neural correlates of cortisol regulation in response to stress. Neuroimage. 2009;47(3):864–71.
45. Urry HL, van Reekum CM, Johnstone T, et al. Amygdala and ventromedial prefrontal cortex are inversely coupled during regulation of negative affect and predict the diurnal pattern of cortisol secretion among older adults. J Neurosci. 2006;26(16):4415–25.
46. Lenze EJ, Wetherell JL. Bringing the bedside to the bench, and then to the community: a prospectus for intervention research in late-life anxiety disorders. Int J Geriatr Psychiatry. 2009;24(1):1–14.
47. Mantella RC, Butters MA, Amico JA, et al. Salivary cortisol is associated with diagnosis and severity of late-life generalized anxiety disorder. Psychoneuroendocrinology. 2008;33(6):773–81.
48. Hek K, Direk N, Newson RS, et al. Anxiety disorders and salivary cortisol levels in older adults: a population-based study. Psychoneuroendocrinology. 2013;38(2):300–5.
49. Lenze EJ, Mantella RC, Shi P, et al. Elevated cortisol in older adults with generalized anxiety disorder is reduced by treatment: a placebo-controlled evaluation of escitalopram. Am J Geriatr Psychiatry. 2011;19(5):482–90.
50. Tafet GE, Feder DJ, Abulafia DP, Roffman SS. Regulation of hypothalamic-pituitary-adrenal activity in response to cognitive therapy in patients with generalized anxiety disorder. Cogn Affect Behav Neurosci. 2005;5(1):37–40.
51. Kang JE, Cirrito JR, Dong H, Csernansky JG, Holtzman DM. Acute stress increases interstitial fluid amyloid-beta via corticotropin-releasing factor and neuronal activity. Proc Natl Acad Sci U S A. 2007;104(25):10673–8.
52. Green KN, Billings LM, Roozendaal B, McGaugh JL, LaFerla FM. Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer’s disease. J Neurosci. 2006;26(35):9047–56.
53. Csernansky JG, Dong H, Fagan AM, et al. Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia. Am J Psychiatry. 2006;163(12):2164–9.
54. Mulsant BHP. Psychopharmacology. In: Thakur M, Blazer DG, Steffens DC, editors. Clinical manual of geriatric psychiatry. Washington DC: American Psychiatric Publishing, Inc; 2014.
55. Pollock B, Forsyth C, Bies R. The critical role of clinical pharmacology in geriatric psychopharmacology. Clin Pharmacol Ther. 2009;85(1):89–93.
56. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(5):403–39. Recent consensus paper outlining guidelines for treatment of anxiety disorders.
57. Schuurmans J, Comijs H, Emmelkamp PM, et al. A randomized, controlled trial of the effectiveness of cognitive-behavioral therapy and sertraline versus a waitlist control group for anxiety disorders in older adults. Am J Geriatr Psychiatry. 2006;14(3):255–63.
58. Lenze EJ, Mulsant BH, Shear MK, et al. Efficacy and tolerability of citalopram in the treatment of late-life anxiety disorders: results from an 8-week randomized, placebo-controlled trial. Am J Psychiatry. 2005;162(1):146–50.
59. Mokhber N, Azarpazhooh MR, Khajehdaluee M, Velayati A, Hopwood M. Randomized, single-blind, trial of sertraline and buspirone for treatment of elderly patients with generalized anxiety disorder. Psychiatry Clin Neurosci. 2010;64(2):128–33.
60. Katz IR, Reynolds 3rd CF, Alexopoulos GS, Hackett D. Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials. J Am Geriatr Soc. 2002;50(1):18–25.
61. Davidson J, Allgulander C, Pollack MH, et al. Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies. Hum Psychopharmacol. 2008;23(6):519–26.
62. Laghrissi-Thode F, Pollock BG, Miller MC, Mulsant BH, Altieri L, Finkel MS. Double-blind comparison of paroxetine and nortriptyline on the postural stability of late-life depressed patients. Psychopharmacol Bull. 1995;31(4):659–63.
63. Yuan Y, Tsoi K, Hunt RH. Selective serotonin reuptake inhibitors and risk of upper GI bleeding: confusion or confounding? Am J Med. 2006;119(9):719–27.
64. Diem SJ, Blackwell TL, Stone KL, et al. Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med. 2007;167(12):1240–5.
65. Fabian TJ, Amico JA, Kroboth PD, et al. Paroxetine-induced hyponatremia in older adults: a 12-week prospective study. Arch Intern Med. 2004;164(3):327–32.
66. Schutters SI, Van Megen HJ, Van Veen JF, Denys DA, Westenberg HG. Mirtazapine in generalized social anxiety disorder: a randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol. 2010;25(5):302–4.
67. Benitez CI, Smith K, Vasile RG, Rende R, Edelen MO, Keller MB. Use of benzodiazepines and selective serotonin reuptake inhibitors in middle-aged and older adults with anxiety disorders: a longitudinal and prospective study. Am J Geriatr Psychiatry. 2008;16(1):5–13.
68. Landi F, Onder G, Cesari M, Barillaro C, Russo A, Bernabei R. Psychotropic medications and risk for falls among community-dwelling frail older people: an observational study. J Gerontol A Biol Sci Med Sci. 2005;60(5):622–6.
69. Gray SL, LaCroix AZ, Hanlon JT, et al. Benzodiazepine use and physical disability in community-dwelling older adults. J Am Geriatr Soc. 2006;54(2):224–30.
70. Paterniti S, Dufouil C, Alperovitch A. Long-term benzodiazepine use and cognitive decline in the elderly: the Epidemiology of Vascular Aging Study. J Clin Psychopharmacol. 2002;22(3):285–93.
71. Uchida H, Suzuki T, Mamo DC, et al. Benzodiazepine and antidepressant use in elderly patients with anxiety disorders: a survey of 796 outpatients in Japan. J Anxiety Disord. 2009;23(4):477–81.
72. Montgomery S, Chatamra K, Pauer L, Whalen E, Baldinetti F. Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br J Psychiatry. 2008;193(5):389–94.
73. Kasper S, Iglesias-Garcia C, Schweizer E, et al. Pregabalin long-term treatment and assessment of discontinuation in patients with generalized anxiety disorder. Int J Neuropsychopharmacol. 2014;17(5):685–95.
74. Kreys TJ, Phan SV. A literature review of quetiapine for generalized anxiety disorder. Pharmacotherapy. 2015;35(2):175–88.
75. Mezhebovsky I, Magi K, She F, Datto C, Eriksson H. Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder. Int J Geriatr Psychiatry. 2013;28(6):615–25.
76. Morinigo A, Blanco M, Labrador J, Martin J, Noval D. Risperidone for resistant anxiety in elderly persons. Am J Geriatr Psychiatry. 2005;13(1):81–2.
77. Rampello L, Alvano A, Raffaele R, Malaguarnera M, Vecchio I. New possibilities of treatment for panic attacks in elderly patients: escitalopram versus citalopram. J Clin Psychopharmacol. 2006;26(1):67–70.
78. Sheikh JI, Lauderdale SA, Cassidy EL. Efficacy of sertraline for panic disorder in older adults: a preliminary open-label trial. Am J Geriatr Psychiatry. 2004;12(2):230.
79. Pinquart M, Duberstein PR. Treatment of anxiety disorders in older adults: a meta-analytic comparison of behavioral and pharmacological interventions. Am J Geriatr Psychiatry. 2007;15(8):639–51.
80. Hofmann SG, Smits JA. Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. J Clin Psychiatry. 2008;69(4):621–32.
81. Stanley MA, Beck JG, Novy DM, et al. Cognitive-behavioral treatment of late-life generalized anxiety disorder. J Consult Clin Psychol. 2003;71(2):309–19.
82. Wetherell JL, Gatz M, Craske MG. Treatment of generalized anxiety disorder in older adults. J Consult Clin Psychol. 2003;71(1):31–40.
83. Mohlman J. Psychosocial treatment of late-life generalized anxiety disorder: current status and future directions. Clin Psychol Rev. 2004;24(2):149–69.
84. Thorp SR, Ayers CR, Nuevo R, Stoddard JA, Sorell JT, Wetherell JL. Meta-analysis comparing different behavioral treatments for late-life anxiety. Am J Geriatr Psychiatry. 2009;17:105–115.
85. Thorp SR, Ayers CR, Nuevo R, Stoddard JA, Sorrell JT, Wetherell JL. Meta-analysis comparing different behavioral treatments for late-life anxiety. Am J Geriatr Psychiatry. 2009;17(2):105–15.
86. Mohlman J, Gorman JM. The role of executive functioning in CBT: a pilot study with anxious older adults. Behav Res Ther. 2005;43(4):447–65.
87. Mohlman J. Executive skills in older adults with GAD: relations with clinical variables and CBT outcome. J Anxiety Disord. 2013;27(1):131–9.
88. Barrowclough C, King P, Colville J, Russell E, Burns A, Tarrier N. A randomized trial of the effectiveness of cognitive-behavioral therapy and supportive counseling for anxiety symptoms in older adults. J Consult Clin Psychol. 2001;69(5):756–62.
89. Wetherell JL, Stoddard JA, White KS, et al. Augmenting antidepressant medication with modular CBT for geriatric generalized anxiety disorder: a pilot study. Int J Geriatr Psychiatry. 2011;26(8):869–75.
90. Lenze EJ, Hickman S, Hershey T, et al. Mindfulness-based stress reduction for older adults with worry symptoms and co-occurring cognitive dysfunction. Int J Geriatr Psychiatry. 2014;29(10):991–1000.
91. Wetherell JL, Afari N, Ayers CR, et al. Acceptance and commitment therapy for generalized anxiety disorder in older adults: a preliminary report. Behav Ther. 2011;42(1):127–34.
92. Baldwin DS, Polkinghorn C. Evidence-based pharmacotherapy of Generalized Anxiety Disorder. Int J Neuropsychopharmacol. 2005;8:293–302.